Innovating Works

GENEXPLAIN

Desconocido
Chrom_rare: Unveiling the molecular basis of chromatinopathies to delineate innovative therapeutic solutions GENEXPLAIN GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 Chromatinopathies (CPs) are a group of rare genetic diseases, which share clinical features as well as causal genetic alterations, leading t...
2022-06-14 - 2026-12-31 | Financiado
PD-MitoQUANT: PD MitoQUANT A quantitative approach towards the characterisation of mitochondrial dysfunction in... GENEXPLAIN GMBH participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is...
2019-02-19 - 2022-07-31 | Financiado
COLOSSUS: Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer Systems based patient stra... GENEXPLAIN GMBH participó en un H2020: H2020-SC1-2016-2017 Colorectal cancer (CRC) is the third most common cancer in Europe with c. 420,000 cases and 150,000 related deaths in 2012. Of total CRC cas...
2017-11-21 - 2023-06-30 | Financiado
GLIOTRAIN: Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational... GENEXPLAIN GMBH participó en un H2020: H2020-MSCA-ITN-2017 Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patien...
2017-08-29 - 2021-08-31 | Financiado
OPTOGENERAPY: Optogenetic Protein Therapy for Multiple Sclerosis GENEXPLAIN GMBH participó en un H2020: H2020-NMBP-2016-2017 Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment. The aim is to develop...
2016-11-23 - 2020-01-31 | Financiado
miRNA-DisEASY: microRNA biomarkers in an innovative biophotonic sensor kit for high specific diagnosis GENEXPLAIN GMBH participó en un H2020: H2020-MSCA-RISE-2015 Since 2001’s discovery of microRNAs (miRNAs) in humans, progress in genomics and transcriptomics has increased our comprehension of gene exp...
2015-11-20 - 2019-11-30 | Financiado
SYSCOL: Systems Biology of Colorectal Cancer GENEXPLAIN GMBH participó en un FP7: Colorectal cancer (CRC) is one of the most common cancers in both males and females, and it is perhaps the best understood of all epithelial...
Financiado
RESOLVE: A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with meta... GENEXPLAIN GMBH participó en un FP7: Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the dist...
Financiado
MIMOMICS: Methods for Integrated analysis of Multiple Omics datasets GENEXPLAIN GMBH participó en un FP7: MIMOmics develops statistical methods for the integrated analysis of metabolomics, proteomics, glycomics and genomic datasets in large studi...
Financiado
SYSMEDIBD: Systems medicine of chronic inflammatory bowel disease GENEXPLAIN GMBH participó en un FP7: Inflammatory bowel disease (IBD) is a major health problem with severe co-morbidities, requiring life-long treatment. Oscillating processes,...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.